Discovery is aimed to find effective and safe treatments for COVID-19.
DisCoVeRy has implemented a new a new therapeutic arm to test a long-acting antibody (LAAB) combination developed by AstraZeneca. Click here for more information.
The initial design was composed of four different treatments evaluated in adults (≥18-year-old) hospitalized for COVID-19, added to standard cares (oxygen therapy, drugs in prevention of phlebitis and pulmonary embolism, and dexamethasone which reduces inflammation and lung damage) and compared to standard cares alone. Their efficacy was evaluated 15 days after treatment initiation. Click here for more information.
This study is a multi-centre/country trial involving ten European countries, led by the French national institute for Health and Medical Research (Inserm), and is conducted in partnership with the Solidarity trial, coordinated by the World Health Organisation (WHO).
The European Commission supports the European extension of the DisCoVeRy trial through the 5 years funding of a European network for research and preparedness for pandemics and emerging infectious diseases – EU-RESPONSE. EU-RESPONSE is coordinated by Inserm.